DiviTum® TKa assay

DEVICE2 trials

Sponsors

Washington University School of Medicine

Conditions

Breast CancerCancer of the BreastMetastatic Breast CancerUnresectable Breast Cancer

Unknown Phase

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

RecruitingNCT04968964

Washington University School of MedicineBreast Cancer, Cancer of the Breast

Start: 2022-03-07End: 2030-09-30Target: 55Updated: 2026-07-06

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

RecruitingNCT05977036

Washington University School of MedicineMetastatic Breast Cancer, Unresectable Breast Cancer

Start: 2024-09-25End: 2034-09-30Target: 65Updated: 2025-12-17

Related Papers

Abstract PO1-15-06: Serum thymidine kinase activity as a “real-time” clinical biomarker of tumor response to CDK4/6 inhibition in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer

Cancer Research2024-05-02

Abstract OT3-11-01: TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity

Cancer Research2023-03-011 citations